Literature DB >> 27543757

Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus.

Su-Jin Park1, Young-Jae Si1, Jihye Kim2, Min-Suk Song1, Se-Mi Kim1, Eun-Ha Kim1, Hyeok-Il Kwon1, Young-Il Kim1, Ok-Jun Lee1, Ok Sarah Shin3, Chul-Joong Kim4, Eui-Cheol Shin2, Young Ki Choi5.   

Abstract

To investigate cross-protective vaccine efficacy of highly-pathogenic avian influenza H5N1 viruses against a recent HPAI H5N8 virus, we immunized C57BL/6 mice and ferrets with three alum-adjuvanted inactivated whole H5N1 vaccines developed through reverse-genetics (Rg): [Vietnam/1194/04xPR8 (clade 1), Korea/W149/06xPR8 (clade 2.2), and Korea/ES223N/03xPR8 (clade 2.5)]. Although relatively low cross-reactivities (10-40 HI titer) were observed against heterologous H5N8 virus, immunized animals were 100% protected from challenge with the 20 mLD50 of H5N8 virus, with the exception of mice vaccinated with 3.5μg of Rg Vietnam/1194/04xPR8. Of note, the Rg Korea/ES223N/03xPR8 vaccine provided not only effective protection, but also markedly inhibited viral replication in the lungs and nasal swabs of vaccine recipients within five days of HPAI H5N8 virus challenge. Further, we demonstrated that antibody-dependent cell-mediated cytotoxicity (ADCC) of an antibody-coated target cell by cytotoxic effector cells also plays a role in the heterologous protection of H5N1 vaccines against H5N8 challenge.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADCC; Cross-protection; H5N8; HPAI H5N1; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 27543757     DOI: 10.1016/j.virol.2016.08.010

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.

Authors:  Xiangjie Sun; Jessica A Belser; Joanna A Pulit-Penaloza; Hannah M Creager; Zhu Guo; Stacie N Jefferson; Feng Liu; Ian A York; James Stevens; Taronna R Maines; Daniel B Jernigan; Jacqueline M Katz; Min Z Levine; Terrence M Tumpey
Journal:  Virology       Date:  2017-05-26       Impact factor: 3.616

2.  Preparation and immunogenicity of influenza virus-like particles using nitrocellulose membrane filtration.

Authors:  Young Chan Park; Jae Min Song
Journal:  Clin Exp Vaccine Res       Date:  2017-01-25

3.  Poly-γ-Glutamic Acid Complexed With Alum Induces Cross-Protective Immunity of Pandemic H1N1 Vaccine.

Authors:  Quyen Thi Nguyen; Chaewon Kwak; Wang Sik Lee; Jaemoo Kim; Jinyoung Jeong; Moon Hee Sung; Jihyun Yang; Haryoung Poo
Journal:  Front Immunol       Date:  2019-07-11       Impact factor: 7.561

Review 4.  Influenza and Antibody-Dependent Cellular Cytotoxicity.

Authors:  Tarra A Von Holle; M Anthony Moody
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

Review 5.  Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review.

Authors:  Adinda Kok; Ron A M Fouchier; Mathilde Richard
Journal:  Vaccines (Basel)       Date:  2021-12-10

Review 6.  Avian Influenza A Virus Pandemic Preparedness and Vaccine Development.

Authors:  Rory D de Vries; Sander Herfst; Mathilde Richard
Journal:  Vaccines (Basel)       Date:  2018-07-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.